½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1193137

¸Åµ¶ ¸é¿ªÁø´Ü ½ÃÀå : Á¦Ç° À¯Çüº°(ºÐ¼®±â, Å°Æ®, ½Ã¾à), ±â¼úº°(CLIA, ELISA), ÃÖÁ¾ »ç¿ëÀÚº°(Ç÷¾× ÀºÇà, Áø´Ü ½ÇÇè½Ç, º´¿ø) - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2021-2031³â)

Syphilis Immunoassay Diagnostics Market By Product Type (Analyzers, Kits and reagents), By Technology (CLIA, ELISA), By End User (Blood Banks, Diagnostic Labs, Hospitals): Global Opportunity Analysis and Industry Forecast, 2021-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Allied Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 247 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¸Åµ¶ ¸é¿ªÁø´ÜÀÇ ¼¼°è ½ÃÀåÀº 2021³â¿¡ 3¾ï 1550¸¸ ´Þ·¯, 2031³â¿¡´Â 4¾ï 4600¸¸ ´Þ·¯¿¡ À̸£·¶À¸¸ç, 2022³âºÎÅÍ 2031³â±îÁöÀÇ CAGRÀº 3.5%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¸Åµ¶Àº ¼ºÀû Á¢ÃËÀ¸·Î °¨¿°µÇ´Â ¸¸¼º ¹ÚÅ׸®¾Æ °¨¿°ÀÔ´Ï´Ù. ¸Åµ¶Àº Treponema pallidumÀ¸·Î ºÒ¸®´Â ¹ÚÅ׸®¾ÆÀÇ ÀÏÁ¾¿¡ ÀÇÇØ À¯¹ßµË´Ï´Ù. ¸Åµ¶¿¡´Â 1Â÷¼º, 2Â÷¼º, Àẹ¼º, 3Â÷¼ºÀÇ 4°¡Áö ´Ü°è°¡ ÀÖ½À´Ï´Ù. ¸Åµ¶ÀÇ Ãʱ⠴ܰè´Â »ç¶÷ÀÌ ¹ÚÅ׸®¾Æ¿¡ °¨¿°µÈ ÈÄ ¾à 3-4ÁÖ ÈÄ¿¡ ¹ß»ýÇÕ´Ï´Ù. ¸Åµ¶ÀÇ µÎ ¹ø° ´Ü°è¿¡¼­´Â ÇǺΠ¹ßÁø°ú ÀÎÈÄÅëÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¦1Â÷, Á¦2Â÷¿Í Áõ»óÀÌ »ç¶óÁ® °¡°í, ¸Åµ¶ÀÇ Àẹ±â¿¡´Â ´«¿¡ ¶ç´Â Áõ»óÀº ³ª¿ÀÁö ¾Ê°Ô µË´Ï´Ù. ¼¼ ¹ø° ´Ü°è¿¡¼­´Â ½Ç¸í, û·Â »ó½Ç, Á¤½Å »óÅ µîÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Áúº´ÀÇ Áø´ÜÀº ¸Åµ¶ÀÇ ½ºÅ©¸®´× °Ë»ç·Î ¼ö¾×À» äÃë ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸Åµ¶ÀÇ Ç÷¾× °Ë»ç´Â ¸Åµ¶±Õ (Treponema pallidum)À» ÇâÇÑ Ç×üÀÇ À¯¹«¸¦ Á¶»çÇÕ´Ï´Ù. ¸Åµ¶ÀÇ °Ë»ç¹ýÀ¸·Î´Â T pallidumÀÇ ¹Ì¼¼Ç÷±¸ ÀÀÁý¹ý, T pallidum ÀÔÀÚ ÀÀÁý¹ý, T pallidum Ç÷±¸ ÀÀÁý¹ý, Çü±¤ Æ®·¹Æ÷³×ÀÌ¸Ó Ç×ü Èí¼ö(FTA-ABS) °Ë»ç, Æ®·¹Æ÷³×ÀÌ¸Ó Ç×ü¸¦ °ËÃâÇÏ´Â È­ÇÐ ¹ß±¤ ¸é¿ª ÃøÁ¤¹ý, È¿¼Ò ¸é¿ª ÃøÁ¤¹ýÀ» »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸Åµ¶ ¸é¿ªºÐ¼® Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¼º°¨¿°°ú Çì·ÎÀÎ, ÄÚÄ«ÀÎ, °¢¼ºÁ¦, ´ë¸¶ÃÊ, º¥Á¶µð¾ÆÁ¦ÇÉ, ¾ËÄÚ¿Ã µî ´Ù¼öÀÇ ¾à¹°ÀÇ ¿µÇâ ÇÏ¿¡¼­ ¼º±³¼·ÀÇ ºñÀ²ÀÌ Áõ°¡ÇÏ´Â µî »çȸ°æÁ¦Àû ¿äÀÎÀÇ »ó½Â¿¡ ÀÇÇØ ÃÊ·¡µÈ´Ù. ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ä¡¸íÀûÀÎ ¸Åµ¶ °¨¿°·üÀÇ Áõ°¡, °Ë»ç ½Ã¼³ÀÇ ±ÞÁõ, °Ë»ç ±â¼úÀÇ º¸±Þ, ±× ÀÚ¸®¿¡¼­ÀÇ °Ë»ç°¡ °¡´ÉÇØÁø °Íµµ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2020³â¿¡´Â Ŭ¶ó¹Ìµð¾Æ(1¾ï2900¸¸), ÀÓº´(8200¸¸), ¸Åµ¶(710¸¸), Æ®¸®Äڸ𳪽º(1¾ï5600¸¸) µî 4°¡Áö STI Áß Çϳª¿¡ »õ·Î °¨¿°µÈ »ç¶÷Àº 3¾ï 7400¸¸¸íÀ¸·Î ÃßÁ¤µË´Ï´Ù. ±×·¯³ª ½ÅÈï±¹¿¡¼­´Â °³ÀÎÀÇ Áö½Ä ºÎÁ·ÀÌ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ý´ë·Î ¹Ì°³Ã´ ½ÅÈï±¹ÀÇ ³ôÀº ¼ºÀå ±âȸ´Â ÀÌ ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå °³¿ä

  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä Á¶»ç °á°ú
    • ÁÖ¿ä ÅõÀÚ Æ÷ÄÏ
  • Porter's Five Forces ºÐ¼®
  • ÁÖ¿ä ±â¾÷ÀÇ Æ÷Áö¼Å´×
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø ¿äÀÎ
    • ¾ïÁ¦ ¿äÀÎ
    • ±âȸ
  • COVID-19 ¿µÇ⠺м®

Á¦4Àå ¸Åµ¶ ¸é¿ªÁø´Ü ½ÃÀå : Á¦Ç° À¯Çüº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • ºÐ¼®ÀåÄ¡
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • Å°Æ®¡¤½Ã¾à
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°

Á¦5Àå ¸Åµ¶ ¸é¿ªÁø´Ü ½ÃÀå : ±â¼úº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • CLIA
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • ELISA
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°

Á¦6Àå ¸Åµ¶ ¸é¿ªÁø´Ü ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • Ç÷¾×ÀºÇà
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • Áø´Ü ½ÇÇè½Ç
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°
  • º´¿ø
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå Á¡À¯À² ºÐ¼® : ±¹°¡º°

Á¦7Àå ¸Åµ¶ ¸é¿ªÁø´Ü ½ÃÀå : Áö¿ªº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • ºÏ¹Ì
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç° À¯Çüº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±â¼úº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
  • À¯·´
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç° À¯Çüº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±â¼úº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • µ¶ÀÏ
      • ÇÁ¶û½º
      • ¿µ±¹
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´ Áö¿ª
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç° À¯Çüº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±â¼úº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ÀϺ»
      • Áß±¹
      • È£ÁÖ
      • Àεµ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • LAMEA
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç° À¯Çüº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±â¼úº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿£µåÀ¯Àúº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ºê¶óÁú
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ³²¾ÆÇÁ¸®Ä« °øÈ­±¹
      • ±âŸ LAMEA

Á¦8Àå ±â¾÷ Á¤¼¼

  • ¼Ò°³
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÁÖ¿ä 10°³»çÀÇ Á¦Ç° ¸ÅÇÎ
  • °æÀï ´ë½Ãº¸µå
  • °æÇÕÀÇ È÷Æ® ¸Ê
  • ÁÖ¿ä ¹ßÀü

Á¦9Àå ±â¾÷ ÇÁ·ÎÇÊ

  • BioRad Laboratories Inc
  • Danaher Corporation
  • BECTON DICKINSON & COMPANY
  • F. Hoffmann-La Roche AG
  • Siemens Healthineers AG
  • Diasorin SPA
  • Abbott Laboratories
  • Fujirebio
  • BioMerieux SA
  • Shenzhen New Industries Biomedical Engineering Co. Ltd
ksm 23.03.27

The global syphilis immunoassay diagnostics market was valued at $315.5 million in 2021, and is projected to reach $446.0 million by 2031, registering a CAGR of 3.5% from 2022 to 2031.

Syphilis is a chronic bacterial infection that can be transmitted through sexual contact. It is caused by a type of bacteria known as Treponema pallidum. The four stages of syphilis include primary, secondary, latent, and tertiary. The primary stage of syphilis occurs about 3 to 4 weeks after a person contracts the bacteria. Skin rashes and a sore throat may develop during the second stage of syphilis. The primary and secondary symptoms disappear, and there won't be any noticeable symptoms at the latent stage of syphilis. The tertiary stage can cause blindness, loss of hearing, and mental health conditions. The diagnosis of this disease includes the collection of spinal fluid for the screening test of syphilis. Moreover, the blood test for syphilis tests for antibodies directed at the syphilis organism (Treponema pallidum). The available tests for syphilis include the microhemagglutination assay for T pallidum, the T pallidum particle agglutination, the T pallidum hemagglutination assay, the fluorescent treponemal antibody absorbed (FTA-ABS) test, and chemoluminescence immunoassays and enzyme immunoassays that detect Treponemal antibodies.

The growth of the syphilis immunoassay diagnostics market is driven by rising in socioeconomic factors such as sexually transmitted diseases and an increase in the proportion of sex under the influence of numerous drugs such as heroin, cocaine, methamphetamine, cannabis, benzodiazepines, and alcohol. Moreover, the increase in rates of fatal syphilis infections, the surge in testing facilities, the widespread use of technology in testing, and the availability of on-the-spot testing also help in the growth of the market. For instance, according to the data from World Health Organization (WHO), there were an estimated 374 million new infections with 1 of 4 STIs like chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million), and trichomoniasis (156 million) in 2020. However, a lack of knowledge among individuals in emerging economies is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.

The global syphilis immunoassay diagnostics market is segmented based on product type, technology, end-user, and region. As per product type, the market is divided into analyzers and kits & reagents. Depending on the technology, the market is bifurcated into CLIA and ELISA. According to end users, the market is classified into blood banks, diagnostic labs, and hospitals. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the syphilis immunoassay diagnostics market analysis from 2021 to 2031 to identify the prevailing syphilis immunoassay diagnostics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the syphilis immunoassay diagnostics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global syphilis immunoassay diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product Type

  • Analyzers
  • Kits and reagents

By Technology

  • CLIA
  • ELISA

By End User

  • Blood Banks
  • Diagnostic Labs
  • Hospitals

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • BioRad Laboratories Inc
    • Danaher Corporation
    • BECTON DICKINSON & COMPANY
    • , F. Hoffmann-La Roche AG
    • Siemens Healthineers AG
    • Diasorin S.P.A
    • Abbott Laboratories
    • Fujirebio
    • , BioMerieux SA
    • Shenzhen New Industries Biomedical Engineering Co. Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Analyzers
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Kits and reagents
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 CLIA
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 ELISA
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Blood Banks
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Diagnostic Labs
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Hospitals
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Product Type
    • 7.2.3 North America Market size and forecast, by Technology
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Product Type
      • 7.2.5.1.3 Market size and forecast, by Technology
      • 7.2.5.1.4 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Product Type
      • 7.2.5.2.3 Market size and forecast, by Technology
      • 7.2.5.2.4 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Product Type
      • 7.2.5.3.3 Market size and forecast, by Technology
      • 7.2.5.3.4 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Product Type
    • 7.3.3 Europe Market size and forecast, by Technology
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Product Type
      • 7.3.5.1.3 Market size and forecast, by Technology
      • 7.3.5.1.4 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Product Type
      • 7.3.5.2.3 Market size and forecast, by Technology
      • 7.3.5.2.4 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Product Type
      • 7.3.5.3.3 Market size and forecast, by Technology
      • 7.3.5.3.4 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Product Type
      • 7.3.5.4.3 Market size and forecast, by Technology
      • 7.3.5.4.4 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Product Type
      • 7.3.5.5.3 Market size and forecast, by Technology
      • 7.3.5.5.4 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Product Type
      • 7.3.5.6.3 Market size and forecast, by Technology
      • 7.3.5.6.4 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Product Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Technology
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Product Type
      • 7.4.5.1.3 Market size and forecast, by Technology
      • 7.4.5.1.4 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Product Type
      • 7.4.5.2.3 Market size and forecast, by Technology
      • 7.4.5.2.4 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Product Type
      • 7.4.5.3.3 Market size and forecast, by Technology
      • 7.4.5.3.4 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Product Type
      • 7.4.5.4.3 Market size and forecast, by Technology
      • 7.4.5.4.4 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Product Type
      • 7.4.5.5.3 Market size and forecast, by Technology
      • 7.4.5.5.4 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Product Type
      • 7.4.5.6.3 Market size and forecast, by Technology
      • 7.4.5.6.4 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Product Type
    • 7.5.3 LAMEA Market size and forecast, by Technology
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Product Type
      • 7.5.5.1.3 Market size and forecast, by Technology
      • 7.5.5.1.4 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Product Type
      • 7.5.5.2.3 Market size and forecast, by Technology
      • 7.5.5.2.4 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Product Type
      • 7.5.5.3.3 Market size and forecast, by Technology
      • 7.5.5.3.4 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Product Type
      • 7.5.5.4.3 Market size and forecast, by Technology
      • 7.5.5.4.4 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 BioRad Laboratories Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Danaher Corporation
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 BECTON DICKINSON & COMPANY
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 , F. Hoffmann-La Roche AG
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Siemens Healthineers AG
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Diasorin S.P.A
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Abbott Laboratories
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Fujirebio
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 , BioMerieux SA
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Shenzhen New Industries Biomedical Engineering Co. Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦